PETVOTCSurgical & Medical Instruments & ApparatusUS GAAP · USD

PetVivo Holdings, Inc.

PetVivo Holdings, Inc. is a U.S.-based animal health company focused on veterinary medical devices and therapeutics. Its core commercial product is Spryng®, which is sold to veterinarians and distributed through animal-health wholesalers and distribution partners.

Revenue1.1m USD
+0.8 %y/y
Operating profit (EBIT)-9.1m USD
−12.5 %y/y
EBIT margin-793.9%
−82.6 ppy/y
Net income-10.5m USD
−24.7 %y/y
Free cash flow-6.1m USD
−13.5 %y/y

Fiscal year 2026 · change from previous year

Development 2021–2026

-12.5-10.0-7.5-5.0-2.50.02.5m USD2021: 0.01 m USD2021: EBIT -2.0 m USD20212022: EBIT -5.1 m USD20222023: 0.92 m USD2023: EBIT -8.7 m USD20232024: 0.97 m USD2024: EBIT -11 m USD20242025: 1.1 m USD2025: EBIT -8.1 m USD20252026: 1.1 m USD2026: EBIT -9.1 m USD20261.1-9.1
RevenueOperating profit (EBIT)

Business

Share of revenue
Spryng® product sales100 %

Sales of the company's lead veterinary medical device used in animal care settings.

Direct veterinary sales0 %

Sales made directly to veterinarians through the company's own sales efforts.

Distributor sales0 %

Sales routed through animal-health distribution partners such as MWI, Covetrus, Vedco, and Clipper.

Customers

PetVivo sells primarily into the veterinary market, where veterinarians buy Spryng® for use in animal treatment settings. A meaningful portion of sales also flows through animal-health distributors and wholesalers that serve veterinary clinics and practices. The business depends on both end-customer adoption by veterinarians and the ability of distribution partners to place product efficiently.

Veterinarians

Buy Spryng® directly for use in treating animal patients and for clinic inventory.

Animal-health distributors

Purchase and resell Spryng® to veterinary customers through established distribution networks.

Veterinary clinics and practices

Use or stock the product as part of routine animal care and treatment workflows.

Pet owners

Influence demand indirectly through willingness to pursue veterinarian-recommended treatments.

Strategy

PetVivo’s strategy is to expand commercialization of Spryng® through a mix of direct sales and third-party distribution. The company is also focused on building brand awareness and product promotion in the veterinary market to increase adoption and market penetration.

Expand U.S. commercialization of Spryng®Short term

Revenue growth depends on broader veterinarian adoption and stronger channel execution.

Strengthen distribution relationshipsShort term

Third-party distributors extend market reach and are important to product placement.

Improve marketing and product promotionMedium term

Awareness and promotion are necessary to drive veterinarian demand in a competitive market.

Geography

PetVivo is headquartered in the United States and its commercial activity is centered on the U.S. veterinary market. The company’s reported distribution relationships and direct sales efforts are focused on U.S. veterinarians, making domestic adoption the key geography for revenue generation. No country-level revenue breakdown was disclosed in the provided excerpts.

Risks

PetVivo faces execution risk because its business depends on building a sales force, managing distributors, and converting veterinarians into repeat customers. It also operates in a highly competitive animal-health market where larger companies have greater resources, and its small scale increases sensitivity to channel loss, brand weakness, and financing constraints.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Going-concern and financing risk1Dependence on Spryng® commercialization2Loss or disruption of distribution agreements3Nasdaq delisting / OTCQB trading status4Competition from larger animal-health companies5
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Going-concern and financing riskImpact: CriticalLikelihood: High

    The company has disclosed substantial doubt about its ability to continue as a going concern, making access to capital critical.

    Exposure: Equity financing and operating runway

  2. Dependence on Spryng® commercializationImpact: HighLikelihood: High

    The company’s revenue base is concentrated in a single lead product, so weak adoption would directly limit growth.

    Exposure: Spryng®

  3. Loss or disruption of distribution agreementsImpact: HighLikelihood: High

    A large share of revenue is generated through distributors, so partner changes can quickly affect sales reach.

    ExposureMWICovetrusVedcoClipper
  4. Nasdaq delisting / OTCQB trading statusImpact: HighLikelihood: High

    Loss of a senior exchange listing can reduce liquidity, investor access, and financing flexibility.

    Exposure: Public market access

  5. Competition from larger animal-health companiesImpact: MediumLikelihood: High

    Competitors have greater financial, technical, and commercial resources and established brands.

    Exposure: Veterinary therapeutics and devices

Accounting

Judgemental items
Going-concern assessment

Substantial doubt about continuation requires investors to assess financing needs and survival risk.

Impact: Affects audit opinion, disclosure, and valuation assumptions

Stock-based compensation

Shares issued to employees, board members, and consultants create non-cash expense and dilution.

Impact: Impacts operating expenses and share count

Warrants and preferred stock conversions

Equity-linked instruments can change capital structure and require valuation and classification analysis.

Impact: Affects equity, dilution, and potentially fair value measurements

Non-cash consulting consideration

Issuing shares for services requires fair value measurement of compensation expense.

Impact: Affects SG&A and equity balances

Publicly listed companies with a comparable business focus.

Last updated: 24/09/2026